Skip header and navigation

Refine By

1254 records – page 1 of 126.

The 1,600-year-old skeleton of a middle-age Eskimo woman found near Homer in 1974.

https://arctichealth.org/en/permalink/ahliterature2
Source
Alaska. 49(2):27.
Publication Type
Article
Date
1983
Source
Alaska. 49(2):27.
Date
1983
Geographic Location
Multi-National
Publication Type
Article
Physical Holding
Alaska Medical Library
Keywords
Cancer
Fractures
Notes
From: Fortuine, Robert et al. 1993. The Health of the Inuit of North America: A Bibliography from the Earliest Times through 1990. University of Alaska Anchorage. Citation number 191.
Less detail

5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.

https://arctichealth.org/en/permalink/ahliterature275383
Source
Int J Cancer. 2016 Jun 15;138(12):2820-8
Publication Type
Article
Date
Jun-15-2016
Author
Teemu J Murtola
Elina K Karppa
Kimmo Taari
Kirsi Talala
Teuvo L J Tammela
Anssi Auvinen
Source
Int J Cancer. 2016 Jun 15;138(12):2820-8
Date
Jun-15-2016
Language
English
Publication Type
Article
Keywords
5-alpha Reductase Inhibitors - therapeutic use
Aged
Antineoplastic Agents - therapeutic use
Early Detection of Cancer
Finland - epidemiology
Humans
Kaplan-Meier Estimate
Male
Mass Screening
Middle Aged
Multivariate Analysis
Proportional Hazards Models
Prostatic Neoplasms - diagnosis - drug therapy - mortality
Abstract
Randomized clinical trials have shown that use of 5a-reductase inhibitors (5-ARIs) lowers overall prostate cancer (PCa) risk compared to placebo, while the proportion of Gleason 8-10 tumors is elevated. It is unknown whether this affects PCa-specific survival. We studied disease-specific survival by 5-ARI usage in a cohort of 6,537 prostate cancer cases diagnosed in the Finnish Prostate Cancer Screening Trial and linked to the national prescription database for information on medication use. Cox proportional hazards regression was used to estimate hazard ratios and 95% confidence intervals for prostate cancer-specific deaths. For comparison, survival among alpha-blocker users was also evaluated. During the median follow-up of 7.5 years after diagnosis a total of 2,478 men died; 617 due to prostate cancer and 1,861 due to other causes. The risk of prostate cancer death did not differ between 5-ARI users and nonusers (multivariable adjusted HR 0.94, 95% CI 0.72-1.24 and HR 0.98, 95% CI 0.69-1.41 for usage before and after the diagnosis, respectively). Alpha-blocker usage both before and after diagnosis was associated with increased risk of prostate cancer death (HR 1.29, 95% CI 1.08-1.54 and HR 1.56, 95% CI 1.30-1.86, respectively). The risk increase vanished in long-term alpha-blocker usage. Use of 5-ARIs does not appear to affect prostate cancer mortality when used in management of benign prostatic hyperplasia. Increased risk associated with alpha-blocker usage should prompt further exploration on the prognostic role of lower urinary tract symptoms.
PubMed ID
26804670 View in PubMed
Less detail

5th Canadian Melanoma Conference: research frontiers.

https://arctichealth.org/en/permalink/ahliterature133428
Source
Expert Rev Anticancer Ther. 2011 Jun;11(6):845-8
Publication Type
Conference/Meeting Material
Date
Jun-2011
Author
Léon C van Kempen
Author Affiliation
Department of Pathology, McGill University and Lady Davis Institute for Medical Research, Jewish General Hospital, 3755 Cote Ste-Catherine, Montréal, QC, H3T 1E2, Canada. leon.vankempen@mcgill.ca
Source
Expert Rev Anticancer Ther. 2011 Jun;11(6):845-8
Date
Jun-2011
Language
English
Publication Type
Conference/Meeting Material
Keywords
Antineoplastic Agents - pharmacology - therapeutic use
Canada
Disease Progression
Drug Delivery Systems
Early Detection of Cancer
Humans
Melanoma - pathology - therapy
Neoplasm Metastasis
Skin Neoplasms - pathology - therapy
Survival
Abstract
The prospects for the treatment of metastatic melanoma are improving. Whereas previous scientific meetings dedicated to the treatment of metastatic melanoma patients were overshadowed by our inability to improve overall survival or lengthen the time to progression, the results presented at the most recent meetings are hopeful. The 5th Canadian Melanoma Conference held on 24-27 February in Banff (AB, Canada) was nothing short of optimistic. This year's meeting was divided into three themes: basic science and pathology, dermatology and surgery, and immunology and systemic treatment. In addition, dermoscopy case studies were presented, and Hoffmann la Roche sponsored a symposium on the evaluation of treatment for advanced melanoma. It underscored the importance of early detection and patient stratification, based upon the molecular profile of the tumor, in order to optimize the response to targeted therapy.
PubMed ID
21707280 View in PubMed
Less detail

18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.

https://arctichealth.org/en/permalink/ahliterature153281
Source
J Otolaryngol Head Neck Surg. 2008 Oct;37(5):712-7
Publication Type
Article
Date
Oct-2008
Author
Max Dahele
Yee C Ung
Lisa Ehrlich
Jay Silverberg
Judith Balogh
C Shun Wong
Author Affiliation
Departmentof Radiation Oncology, University of Toronto, Edmond Odette Cancer Centre,Toronto, Ontario.
Source
J Otolaryngol Head Neck Surg. 2008 Oct;37(5):712-7
Date
Oct-2008
Language
English
Publication Type
Article
Keywords
Adult
Aged
Biological Markers - blood
Cancer Care Facilities
Carcinoma, Papillary - pathology - radionuclide imaging - surgery
Cohort Studies
Female
Fluorodeoxyglucose F18 - diagnostic use
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Recurrence, Local - pathology - radionuclide imaging - surgery
Neoplasm Staging
Ontario
Positron-Emission Tomography - methods
Reproducibility of Results
Retrospective Studies
Risk assessment
Sensitivity and specificity
Thyroglobulin - blood
Thyroid Neoplasms - pathology - radionuclide imaging - surgery
Thyroidectomy - methods
Time Factors
Treatment Outcome
Young Adult
Abstract
To report the initial experience with combined 18F-fluorodeoxyglucose positron emission tomography (FDG PET)/computed tomography (CT) imaging for suspected recurrent papillary differentiated thyroid cancer (DTC) at Sunnybrook Health Sciences Centre (SHSC), Toronto.
Single institution retrospective study.
Consecutive patients from SHSC who underwent FDG PET/CT imaging for suspected recurrent DTC over a period of 2.5 years were identified and their charts reviewed.
Qualitative appraisal of FDG PET/CT imaging in suspected recurrent DTC.
Sixteen patients (14F, 2M) were identified accounting for 17 FDG PET/CT scans. Three scans (18%) in 3 different patients were reported as suspicious for recurrent disease in the neck (1-3 lesions) and were considered "positive". All were subsequently confirmed pathologically (4-13 positive lymph nodes post operatively). Prior conventional imaging was abnormal in two patients. Two patients had an elevated non-stimulated thyroglobulin (TG)
PubMed ID
19128681 View in PubMed
Less detail

[40 years of the Oncological Service in Ul'ianovsk region].

https://arctichealth.org/en/permalink/ahliterature236114
Source
Vopr Onkol. 1987;33(9):70-3
Publication Type
Article
Date
1987
Author
M A Storozhuk
Source
Vopr Onkol. 1987;33(9):70-3
Date
1987
Language
Russian
Publication Type
Article
Keywords
Cancer Care Facilities - history - organization & administration
History, 20th Century
Hospitals, Special - history
Humans
Mass Screening
Neoplasms - epidemiology
Russia
Abstract
The paper discusses the development of oncological service in Ulyanovsk region since 1946 when a 35-bedded dispensary was opened. By 1984, its capacity had reached 335 beds.
PubMed ID
2958967 View in PubMed
Less detail

50 years of screening in the Nordic countries: quantifying the effects on cervical cancer incidence.

https://arctichealth.org/en/permalink/ahliterature257546
Source
Br J Cancer. 2014 Aug 26;111(5):965-9
Publication Type
Article
Date
Aug-26-2014
Author
S. Vaccarella
S. Franceschi
G. Engholm
S. Lönnberg
S. Khan
F. Bray
Author Affiliation
International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon cedex 08, France.
Source
Br J Cancer. 2014 Aug 26;111(5):965-9
Date
Aug-26-2014
Language
English
Publication Type
Article
Keywords
Early Detection of Cancer - methods
Female
Finland - epidemiology
Humans
Incidence
Mass Screening - methods
Papillomavirus Infections - epidemiology
Scandinavia - epidemiology
Uterine Cervical Neoplasms - epidemiology - virology
Abstract
Nordic countries' data offer a unique possibility to evaluate the long-term benefit of cervical cancer screening in a context of increasing risk of human papillomavirus infection.
Ad hoc-refined age-period-cohort models were applied to the last 50-year incidence data from Denmark, Finland, Norway and Sweden to project expected cervical cancer cases in a no-screening scenario.
In the absence of screening, projected incidence rates for 2006-2010 in Nordic countries would have been between 3 and 5 times higher than observed rates. Over 60,000 cases or between 41 and 49% of the expected cases of cervical cancer may have been prevented by the introduction of screening in the late 1960s and early 1970s.
Our study suggests that screening programmes might have prevented a HPV-driven epidemic of cervical cancer in Nordic countries. According to extrapolations from cohort effects, cervical cancer incidence rates in the Nordic countries would have been otherwise comparable to the highest incidence rates currently detected in low-income countries.
PubMed ID
24992581 View in PubMed
Less detail

The 1990 Nordic Oncology Seminar. Regional treatment of cancer research frontiers and direction of progress. Storlien, Sweden, March 21-24, 1990. Proceedings.

https://arctichealth.org/en/permalink/ahliterature24851
Source
Eur J Surg Suppl. 1991 May;(561):1-90
Publication Type
Conference/Meeting Material
Article
Date
May-1991

1994 behavioral risk factor survey highlights

https://arctichealth.org/en/permalink/ahliterature88229
Source
Alaska's Behavioral Risk Factor Surveillance System 4(1)
Publication Type
Report
Date
May-1996
Behavior and lifestyle play an important part in determining our health status and lifespan. Every day Alaskans make lifestyle choices that profoundly affect their health. Although heredity and environment play a part, the leading causes of death in Alaska (heart disease, cancer and unintentional
  1 document  
Author Affiliation
State of Alaska Department of Health and Social Services
Source
Alaska's Behavioral Risk Factor Surveillance System 4(1)
Date
May-1996
Language
English
Geographic Location
U.S.
Publication Type
Report
File Size
122252
Keywords
Alcohol use
Behavioral risk factors
Breast cancer
Cervical cancer
Chronic Disease
Diabetes
Health care coverage
Health checkups
HIV/AIDS
Nutrition
Overweight
Physical activity
Premature death
Sedentary lifestyle
Tobacco use
Abstract
Behavior and lifestyle play an important part in determining ourhealth status and lifespan. Every day Alaskans make lifestyle choices that profoundly affect their health. Although heredity and environment play a part, the leading causes of death in Alaska (heart disease, cancer and unintentional injuries) are closely related to lifestyle factors. Lifestyle and behavioral factors that affect health include such things as diet, exercise, use of alcohol andtobacco, and preventive health practices. Many premature deathsand disabilities could be prevented through better control of thesebehavioral risk factors.
Documents
Less detail

1995 behavioral risk factor survey highlights

https://arctichealth.org/en/permalink/ahliterature88230
Source
Alaska's Behavioral Risk Factor Surveillance System 5(1)
Publication Type
Report
Date
April-1997
Author Affiliation
State of Alaska Department of Health and Social Services
Source
Alaska's Behavioral Risk Factor Surveillance System 5(1)
Date
April-1997
Language
English
Geographic Location
U.S.
Publication Type
Report
Physical Holding
University of Alaska Anchorage
Keywords
Adult immunizations
Alcohol use
Behavioral risk factors
Breast cancer screening
Cervical cancer screening
Cholesterol screening
Chronic Disease
Colorectal cancer screening
Diabetes
Health care coverage
HIV/AIDS
Hypertension
Overweight
Premature death
Safety belt use
Tobacco use
Abstract
Behavior and lifestyle play an important part in determining ourhealth status and lifespan. Every day Alaskans make lifestyle choices that profoundly affect their health. Although heredity and environment play a part, the leading causes of death in Alaska (heart disease, cancer and unintentional injuries) are closely related to lifestyle factors. Lifestyle and behavioral factors that affect health include such things as diet, exercise, use of alcohol andtobacco, and preventive health practices. Many premature deathsand disabilities could be prevented through better control of thesebehavioral risk factors.
Less detail

1998 Cancer in Alaska : Cancer Incidence and Mortality

https://arctichealth.org/en/permalink/ahliterature287906
Source
Annual Report of the Alaska Cancer Registry, 1998
Publication Type
Book/Book Chapter
Date
2002
1998 Cancer in Alaska Cancer Incidence and Mortality State of Alaska Tony Knowles, Governor Department of Health and Social Services Jay Livey, Commissioner Division of Public Health Karen Pearson, MS, Director Alaska Cancer Registry March 2002 MarMarMarMarMarccccchhhhh
  1 document  
Author
State of Alaska. Department of Health and Social Services. Division of Public Health.
Source
Annual Report of the Alaska Cancer Registry, 1998
Date
2002
Language
English
Geographic Location
U.S.
Publication Type
Book/Book Chapter
Digital File Format
Text - PDF
Physical Holding
Alaska Medical Library
Keywords
Alaska
Cancer
Documents
Less detail

1254 records – page 1 of 126.